Daiichi Sankyo
Munich, Bavaria, Germany · Biopharma, Biotechnology, Health Care
Daiichi Sankyo is a global pharmaceutical company that focuses on innovative and sustainable practices in the development of medicines. The company aims to contribute to the health of patients through its wide-ranging drug development portfolio, particularly in oncology. Additionally, AstraZeneca is a biopharmaceutical company that specializes in the development of medicines for various diseases,
Key facts
- Headquarters
- Munich, Bavaria, Germany
- Employees
- 1,074
- Industries
- Biopharma, Biotechnology, Health Care
- Website
- www.daiichi-sankyo.eu
- Company page
Recent activity at Daiichi Sankyo
- : Daiichi Sankyo Partners with Waiv to Enhance AI-Driven Biomarker Discovery in Oncology.
- : Daiichi Sankyo and GENESIS Pharma Sign Exclusive Agreement for VANFLYTA® in Central and Eastern Europe.
- : Daiichi Sankyo Names Hiroyuki Okuzawa as Chief Executive Officer (CEO) succeeding Sunao Manabe
- : Daiichi Sankyo announces datopotamab deruxtecan's Breakthrough Therapy Designation for advanced EGFR-mutated lung cancer treatment.
Leadership
- Sunao Manabe, Chief Operating Officer
- Mila Tartakovsky, Chief Financial Officer
- Kimberly Craighead, Strategic Hr Professional
- Anita Chen, Head of Human Resources
- Gabriel Sivris, Head of Human Resources
- Neil Albuja, Finance Leader With Deep Industry Experience
- Adam Pateman, Finance and Administration Director
- Tom Gorga, Vice President Finance
- Lalit Kumar Sharma, Experience At Daiichi Sankyo Limited
- Jorge Pérez Pérez, Marketing Director
- Ghassan Mamlouk, Sr. Global Commercial Director Oncology
- Greg Barrett, VP, Marketing
Verified email and direct lines for Daiichi Sankyo’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Daiichi Sankyo in the news
- Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 2026 - Business Wire (May 26, 2026)
- GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. - Business Wire (Mar 05, 2026)
- How Daiichi Sankyo Europe drives growth with digital and analytics - McKinsey & Company (Jan 27, 2023)
- Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization - Business Wire (Aug 24, 2026)
- Change in Leadership at Daiichi Sankyo Europe - Business Wire (Nov 06, 2023)
- Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation - Business Wire (Jan 03, 2024)
- Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA - Business Wire (Jan 07, 2026)
- Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C - Business Wire (Aug 30, 2025)
Companies similar to Daiichi Sankyo
- Supernus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Apellis Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Madrigal Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Arcus Biosciences · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Acadia Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Daiichi Sankyo: questions and answers
What does Daiichi Sankyo do?
Daiichi Sankyo is a global pharmaceutical company that focuses on innovative and sustainable practices in the development of medicines. The company aims to contribute to the health of patients through its wide-ranging drug development portfolio, particularly in oncology. Additionally, AstraZeneca is a biopharmaceutical company that specializes in the development of medicines for various diseases,
Where is Daiichi Sankyo headquartered?
Daiichi Sankyo is headquartered in Munich, Bavaria, Germany.
How many employees does Daiichi Sankyo have?
Daiichi Sankyo has about 1,074 employees.
Who leads Daiichi Sankyo?
Tom Gorga is a Vice President Finance at Daiichi Sankyo.
What is the latest news on Daiichi Sankyo?
On May 09, 2026, Daiichi Sankyo Partners with Waiv to Enhance AI-Driven Biomarker Discovery in Oncology.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy